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Abstract
Background: The blood-brain barrier is compromised
in patients with stroke. The release of neuro-biochem-
ical protein markers, such as neuron specific enolase
(NSE) into the circulation may allow the pathophysio-
logy and prognosis of patients with cerebrovascular
diseases to be evaluated further. The present study
was designed to measure the marker of neuronal
damage, NSE, in saliva and serum of patients with
acute ischemic stroke and patients with stroke related
diseases as a diagnostic and/or monitoring tool for
early prediction of ischemic stroke.
Methods: Salivary and serum NSE concentrations
were measured in 150 individuals. Fifty were patients
recently diagnosed as having ischemic stroke, 75
were gender and age-matched risk-group patients
(patients with hypertension, type 2 diabetes and
ischemic heart disease). Another 25 were gender and
age-matched healthy controls.
Results: Salivary and serum NSE concentrations were
significantly higher than that of healthy controls. The
cut-off threshold for salivary NSE of 3.7 mg/L was
optimum, showing 80% accuracy for differentiation of
ischemic stroke from normal individuals.
Conclusions: Salivary NSE (alone or in combination
with serum) can be used as a valuable diagnostic and
possibly prognostic tool for measurement of neuronal
damage in patients with stroke and stroke-related
diseases.
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Introduction
Stroke or cerebrovascular accidents (CVA) are consid-
ered the third leading cause of death after cardiovas-
cular diseases and cancer (1). The blood-brain barrier
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is compromised in patients with stroke, and the
release of neuro-biochemical protein markers into the
circulation may allow the pathophysiology and prog-
nosis of patients with cerebrovascular diseases to be
evaluated further (2). As a consequence of blood-
brain barrier disruption, antigens found either primar-
ily or exclusively in the central nervous system (CNS),
such as neuron specific enolase (NSE), may leak into
the peripheral circulation (3). NSE is a soluble brain
protein first described by Moore and McGregor in
1965 (4). NSE is a dimeric isoenzyme of the glycolytic
enzyme enolase. It is found in the cytoplasm of neu-
rons and cells of neuro-endocrine differentiation (5).
The measurement of NSE concentrations in serum
and cerebrospinal fluid (CSF) following cerebral
ischemia and traumatic head injury provides a relia-
ble laboratory indicator of the degree of brain cell
damage, and may allow for early prediction of out-
come (6, 7). In patients with stroke, the first NSE peak
is found following admission, followed by a second
increase between days 2–4. The first NSE peak within
7–18 h following onset of stroke may reflect the initial
damage to neuronal tissue, whereas the second
increase may be attributed to secondary mechanisms
of neuronal damage due to edema and an increase in
intracranial pressure (3). Therefore, NSE concentra-
tions can provide early information about neuronal
damage.
Saliva is considered as an ultra filtrate of plasma
(8). Diagnosis of diseases using analysis of saliva is
potentially valuable for children and the elderly, since
collection of fluid is associated with fewer compliance
problems compared with the collection of blood or
CSF. Furthermore, analysis of saliva may provide a
cost-effective approach for screening large popula-
tions.
The present study was designed to measure NSE in
saliva and serum of newly diagnosed patients with
ischemic stroke and patients with stroke-related
diseases as a diagnostic and/or monitoring tool for
early prediction of ischemic stroke.
Patients and methods
One hundred and fifty individuals from the Al-Diwania prov-
ince of Iraq were enrolled in this study. They were catego-
rized into three groups:
The first group (study group) was comprised of 50 patients
(24 males and 26 females) who were recently diagnosed clin-
ically and radiographically (Brain CT-scan) as having ische-
mic stroke. Their age ranged from 45 to 75 years.
The second group (case control group) was comprised of
75 gender and age-matched patients and served as the con-
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Table 2 Mean concentrations of NSE in serum and saliva of ischemic stroke, case controls and negative controls.
Cases Risk group Healthy
(Ischemic stroke)
Hypertension Diabetes Heart diseases
controls
mellitus
Serum NSE concentration, mg/L
Range (7.9–27.2) (6.3–20) (7.4–44.1) (10.2–18.9) (5–12.9)
Mean 17 12.3 18.9 14 8.2
SD 4.5 6.1 16.3 3.2 2.8
SE 1 2.71 7.28 1.41 0.89
p (ANOVA) for difference between 5 study groupss0.01
p (Bonferonni t-test) for difference in mean between
Cases (ischemic stroke)=cases controls (hypertension)s1 wNSx
Cases (ischemic stroke)=cases controls (diabetes mellitus)s1 wNSx
Cases (ischemic stroke)=cases controls (heart diseases)s1 wNSx
Cases (ischemic stroke)=healthy controlss0.011
Cases controls (hypertension)=cases controls (diabetes mellitus)s1 wNSx
Cases controls (hypertension)=cases controls (heart diseases)s1 wNSx
Cases controls (diabetes mellitus)=cases controls (heart diseases)s1 wNSx
Cases controls (hypertension)=healthy controlss1 wNSx
Cases controls (diabetes mellitus)=healthy controlss0.044
Cases controls (heart diseases)=healthy controlss1 wNSx
Salivary NSE concentration, mg/L
Range (2.3–8) (2.6–4.1) (2.7–3.9) (2.7–4) (2.2–3.5)
Mean 4.5 3.3 3.2 3.3 2.9
SD 1.6 0.6 0.5 0.5 0.5
SE 0.35 0.29 0.21 0.24 0.17
p (ANOVA) for difference between 5 study groupss0.006
p (Bonferonni t-test) for difference in mean between
Cases (ischemic stroke)=cases controls (hypertension)s0.4 wNSx
Cases (ischemic stroke)=cases controls (diabetes mellitus)s0.23 wNSx
Cases (ischemic stroke)=cases controls (heart diseases)s0.4 wNSx
Cases (ischemic stroke)=healthy controlss0.009
Cases controls (hypertension)=cases controls (diabetes mellitus)s1 wNSx
Cases controls (hypertension)=cases controls (heart diseases)s1 wNSx
Cases controls (diabetes mellitus)=cases controls (HD)s1 wNSx
Cases controls (hypertension)=healthy controlss1 wNSx
Cases controls (diabetes mellitus)=healthy controlss1 wNSx
Cases controls (heart diseases)=healthy controlss1 wNSx
NS, not significant.
Table 1 Distribution of risk factors in patients with ischemic stroke.
Ischemic stroke Risk factors
patients
Hypertension Diabetes mellitus Heart diseases Smoking Previous transient
ischemic attack
Female 18 (43.9%) 17 (50%) 9 (60%) 6 (23.1%) 4 (50%)
Male 23 (56.1%) 17 (50%) 6 (40%) 20 (76.9%) 4 (50%)
Total 41/50 (82%) 34/50 (68%) 15/50 (30%) 26/50 (52%) 8/50 (16%)
trol or risk group. This group included 25 patients (12 males
and 13 females) with hypertension, 25 patients (11males and
14 females) with type 2 diabetes and 25 patients (11 males
and 14 females) with ischemic heart disease (angina or
myocardial infarction).
The third group (negative control) was comprised of 25
gender and age-matched healthy individuals (12 males and
13 females).
All individuals were evaluated by full medical history and
clinical examination, with laboratory investigations to
exclude any other systemic or local disease that may affect
the parameters examined in this study. Oral and periodontal
examination was done for each individual and any patient
with symptoms and signs of any active oral inflammation,
advanced periodontitis or severe gingivitis were excluded.
All participants gave informed consent and the study
protocol was approved by the Local Ethics Committee of
Al-Diwaniya general teaching hospital.
For NSE analysis: blood and saliva samples were taken
from patients and healthy control following an overnight fast
(8.00–9.00 am). For isolation of serum, 5 mL of blood was
collected from each individual and centrifuged at 3000 rpm
at 48C for 5 min. The supernatant was aspirated and stored
in tubes at –208C until analysis. Saliva samples were col-
lected under restful and quiet circumstances. First, the
mouth was flushed with 100 mL of distilled water and then
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Table 3 Parameters of neuron specific enolase (NSE) when used (positive if Gcut-off value) to diagnose ischemic stroke and
differentiate patients from controls.
Positive if Sensitivity, Specificity, Accuracy, PPV% at pretest PPV% at pretest NPV% at pretest
Gcut-off % % % probabilitys50% probabilitys90% probabilitys10%
value
Serum NSE concentration, mg/L
7.8 100.0 20.0 65.7 55.6 91.8 100.0
14.9 75.0 66.7 71.4 69.3 95.3 96.0
27.0 5.0 93.3 42.8 42.7 87.0 89.8
Salivary NSE concentration, mg/L
2.7 90.0 6.7 54.3 49.1 89.7 85.8
4.2 55.0 100.0 74.3 100.0 100.0 95.2
PPV, positive predictive value; NPV, negative predictive value.
Figure 1 ROC curves for neuron specific enolase (NSE) used to diagnose ischemic stroke and differentiate patients from
controls.
Serum NSE concentration (mg/L): ROC area, 0.677; ps0.08 (ns). Salivary NSE concentration (mg/L): ROC area, 0.763; ps0.008.
whole saliva was collected for 5 min by the subject leaning
forward and spiting saliva into test tubes that were kept in
crushed ice. Immediately following collection, samples were
centrifuged at 3000 rpm at 48C for 5 min. The supernatant
was aspirated and stored at –208C until analysis.
The Can Ag NSE EIA kit (Ref 420-10 Fujirebio Diagnostic
Inc, Goteborg, Sweden) was used in this study. Monoclonal
antibodies (MABs) bind to the g-subunit of NSE, allowing
detection of both the gg and the ag form. Calibrators and
patient samples were incubated with biotinylated anti-NSE
MABE21 and horse radish peroxidase (HRP)-labeled anti-
NSE MABE17 in streptavidin coated microtiter strips, for 1 h
with shaking. After washing, buffered substrate/chromogen
reagent (hydrogen peroxide and 3,3,5,5-tetramethylbenzi-
dine) was added to each well and the enzyme reaction
allowed to proceed. Blue color developed if antigen was
present and the color intensity was proportional to the
amount of NSE present in the sample. The color intensity
was determined using a microtiter plate spectrophotometer
at 405 nm. A calibration curve was constructed by plotting
the absorbance value for each NSE calibrator against the
corresponding NSE concentration of each calibrator (in
mg/L). NSE concentrations in patients samples were deter-
mined from the calibration curve.
All data were analyzed using SPSS statistical package
(SPSS, Version 15, Chicago, IL, USA). Data were expressed
as mean"standard deviation (SD). Differences between
groups were analyzed for significance using a one-way
ANOVA. To discriminate between ischemic stroke cases and
case-controls, and to compare the diagnostic performance
of the test, receiver operating characteristic (ROC) curve
analysis was used. Statistical significance was defined as
p-0.05.
Results
The mean age for patients with ischemic stroke was
58.2 years. Forty-one (82%) were hypertensive, 34
were diabetic, 26 were heavy smokers and eight had
a previous transient ischemic attack (Table 1). Since
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Figure 2 ROC curves for neuron specific enolase (NSE) used to diagnose ischemic stroke and differentiate patients from
negative controls.
Serum NSE concentration (mg/L): ROC area, 0.96; p-0.001. Salivary NSE concentration (mg/L): ROC area, 0.825; ps0.004.
Table 4 Parameters of neuron specific enolase (NSE) when used (positive if Gcut-off value) to diagnose ischemic stroke and
differentiate patients from negative controls.
Positive if Sensitivity, Specificity, Accuracy, PPV% at pretest PPV% at pretest NPV% at pretest
Gcut-off % % % probabilitys50% probabilitys90% probabilitys10%
value
Serum NSE concentration, mg/L
7.8 100.0 60.0 86.7 71.4 95.7 100.0
13.1 85.0 100.0 90.0 100.0 100.0 98.4
Salivary NSE concentration, mg/L
2.3 100.0 20.0 73.3 55.6 91.8 100.0
3.7 70.0 100.0 80.0 100.0 100.0 96.8
the concentrations of NSE in serum and saliva did not
vary with age and gender, the results from males and
females were grouped together.
Mean serum NSE concentrations were significantly
higher than those in healthy controls (17.00"4.5 vs.
8.2"2.80 mg/L). However, concentrations were not
significantly different from those seen in hyperten-
sive, diabetic patients as well as patients with ische-
mic heart diseases (Table 2).
Diabetic patients had significantly higher serum
NSE concentrations than healthy controls. However,
patients with hypertension and patients with ischemic
heart diseases did not show any significant difference
in serum NSE concentrations when compared with
those in healthy controls (Table 2).
Salivary NSE concentrations showed higher NSE
values in patients with ischemic stroke compared to
healthy controls (4.5"1.6 vs. 2.9"0.5 mg/L). Salivary
NSE in patients with ischemic stroke did not show any
significant difference when compared with the risk
group patients (Table 2).
ROC curve analysis was used to show the trade-off
between sensitivity and specificity for different cut-off
values of NSE when used to diagnose ischemic stroke
and differentiate these patients from the risk group
(Figure 1 and Table 3).
The area under ROC curve for salivary NSE was
significantly higher (0.763) (ps0.008) compared to
serum NSE (0.677). For salivary NSE, the optimum
cut-off value was (4.2 mg/L). This value yielded opti-
mum specificity (100%) and reasonable sensitivity
(55%).
ROC curve analysis was also applied for differenti-
ating cases with ischemic stroke from healthy con-
trols (Figure 2 and Table 4). The area under the ROC
curve for serum NSE was significantly higher (0.960)
(p-0.001) compared to salivary NSE (0.825). The opti-
mum cut-off value for serum NSE showing the high-
est diagnostic accuracy (90%) was (G13.1 mg/L). This
cut-off threshold showed optimum specificity (100%)
and reasonable sensitivity (85%). For salivary NSE,
the optimum cut-off value showing the highest diag-
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nostic accuracy (80%) was (G3.7 mg/L). This cut-off
threshold showed optimum specificity (100%) and
reasonable sensitivity (70%).
Discussion
Stroke remains the third leading cause of death and
the second most frequent cause of morbidity in devel-
oped countries. Ischemic stroke accounts for 80% of
all strokes (9). Ischemia causes a cascade of events
that eventually lead to neuronal damage and cell
death (10). NSE is the predominant enolase found in
neural tissue, and the structural characteristics of this
enolase allow for greater stability in high chloride
concentrations compared with enolases in other
organ systems (6). Physiologically, NSE is present in
negligible amounts in the peripheral blood. DeGiorgio
et al. (7) stated that ‘‘the measurement of NSE con-
centrations in serum and CSF following cerebral
ischemia and traumatic head injury provides a relia-
ble laboratory indicator of the degree of brain cell
damage, and may allow early prediction of prognostic
outcome’’. NSE has been used as a serum and CSF
marker of neuronal damage in conditions, such as
head injury, status epilepticus, Creutzfeld-Jackob’s
disease, multi-infarct dementia, brain metastases,
subarachnoid hemorrhage and stroke (11, 12). In the
present study, serum NSE concentrations that are
reported are in accordance with those reported by
others (13, 14). After acute CNS insult, such as cere-
bral infarction, hypoxia, trauma and seizure, the
blood-brain barrier is altered and astroglial disinte-
gration results in leakage of NSE into the CSF and
serum (3, 15). In the present investigation, no statis-
tically significant difference was found between
patients with ischemic stroke and at risk patients.
However, the concentrations of serum NSE in diabetic
patients, only, were similar to those seen in patients
with ischemic stroke, which was significantly
increased. This indicated that diabetic patients
showed some sort of neuronal damage and/or blood-
brain barrier disruption. This finding was in agree-
ment with Hovsepyan et al. (16) who demonstrated a
significant increase in antibodies against NSE in both
type 1 and type 2 diabetic subjects compared to
healthy controls. In hypertensive patients and patients
with ischemic heart diseases, the mean serum NSE
ranked an intermediate values between ischemic
stroke and healthy controls. This may be explained
due to the fact that patients with hypertension and
patients with ischemic heart diseases may also be
associated, to a lesser extent, with alterations in the
integrity of the blood-brain barrier. This can explain
the increased serum NSE concentrations in these
patients. Serum NSE was not an accurate predictor of
ischemic stroke in the ‘‘at risk’’ group of patients.
However, serum NSE with an optimum cut-off value
(G13.1 mg/L) is helpful in differentiating patients with
ischemic stroke from healthy controls. NSE was also
detected in human saliva. To our knowledge, this
study is the first to investigate the presence of NSE in
saliva. In the healthy control group, mean salivary
concentrations were 2.9"0.5 mg/L, with a range
between 2.2–3.5 mg/L. This indicated the presence of
NSE in trace amounts in the saliva of healthy individ-
uals. Salivary NSE was increased in patients with
ischemic stroke and stroke-prone patients. This
makes salivary NSE, using an optimum cut-off value
of G4.2 mg/L, diagnostic in predicting ischemic stroke
in stroke-prone individuals. The presence of NSE in
saliva of patients with ischemic stroke and ‘‘at risk’’
patients may be explained by the fact that the integ-
rity of the blood-brain barrier is disrupted to various
degrees in these patients, and leakage of this enzyme
outside the CNS can be seen in salivary secretion.
Conclusions
NSE is present in human saliva and may be of use as
a diagnostic, and possible prognostic tool, for assess-
ing neuronal damage in patients with stroke and
stroke-related diseases.
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